Drug reactions in children with rheumatic diseases receiving parenteral therapies: 9 years’ experience of a tertiary pediatric rheumatology center
- 21 December 2019
- journal article
- research article
- Published by Springer Nature in Rheumatology International
- Vol. 40 (5) , 771-776
Abstract
Parenteral treatments (either subcutaneous or intravenous) are frequently used in rheumatology practice. In this study, drug side effects in patients who were followed up with a rheumatic disease and treated with parenteral administration methods were evaluated. The drug side effects in children who were followed up with a rheumatic disease and treated with parenteral treatments between 2010 and 2019 were recorded, retrospectively. All parenteral treatments are applied by a clinical nurse specialist (CNS) who is experienced in pediatric rheumatology for 10 years. Four hundred and thirteen patients were evaluated in this study. The mean age was 12.09 ± 5.05 years. Most of them were diagnosed with juvenile idiopathic arthritis (n = 317) and colchicine-resistant familial Mediterranean fever (n = 57). Among the patients, 287 was treated with methotrexate, 130 with etanercept, 90 with adalimumab, 71 with anakinra, 64 with canakinumab, 55 with tocilizumab, seven with rituximab, six with infliximab, and four with abatacept. Two of the patients had a history of drug allergy (ceftriaxone = 1, ranitidine = 1). The most common adverse reactions were as follows: nausea–vomiting in 52, rash in 11, itching in three, chest tightening in two, bruising in two, headache in two, and abdominal pain in one of the patients. Drug side effects were observed after an average of three (1–4) administrations. Antihistaminic and steroids (tocilizumab = 3, infliximab = 1, methotrexate = 1) were administered to five patients due to hypersensitivity reactions. Considering the possible side effects and preparation protocols of parenteral treatments, experienced physicians and nurses are required in the field.Keywords
This publication has 16 references indexed in Scilit:
- Hypersensitivity reactions to biologics used in rheumatologyExpert Review of Clinical Immunology, 2019
- Adverse Events in Patients With Rheumatoid Arthritis and Psoriatic Arthritis Receiving Long-Term Biological Agents in a Real-Life SettingFrontiers in Pharmacology, 2019
- Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meetingPediatric Rheumatology, 2018
- Anti-TNF therapy: past, present and futureInternational Immunology, 2014
- Hypersensitivity reactions to tocilizumab: role of skin tests in diagnosisRheumatology, 2014
- Treating inflammation by blocking interleukin-1 in a broad spectrum of diseasesNature Reviews Drug Discovery, 2012
- Hypersensitivity reactions during treatment with infliximab, etanercept, and adalimumabAnnals of Allergy, Asthma & Immunology, 2012
- Adverse effects of biologics: a network meta-analysis and Cochrane overviewCochrane Database of Systematic Reviews, 2011
- Anti-B cell therapy (Rituximab) in the treatment of autoimmune diseasesLupus, 2005
- A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexateArthritis & Rheumatism, 2004